CYANOTECH Details Executive Equity Awards in Latest DEF 14A
Ticker: CYAND · Form: DEF 14A · Filed: Jul 10, 2025 · CIK: 768408
| Field | Detail |
|---|---|
| Company | Cyanotech Corp (CYAND) |
| Form Type | DEF 14A |
| Filed Date | Jul 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: Executive Compensation, Equity Awards, DEF 14A, Corporate Governance, SEC Filing, Medicinal Chemicals, Botanical Products
Related Tickers: CYAND
TL;DR
**CYANOTECH's executive equity awards are consistent, signaling stable leadership incentives, but lack of financial performance data makes it a neutral hold.**
AI Summary
CYANOTECH CORP's DEF 14A filing, dated July 10, 2025, outlines executive compensation for the fiscal year ending March 31, 2025, and prior years. Gerald R. Cysewski, a named executive officer (PEO), received equity awards, with specific adjustments and inclusions in the summary compensation table for the periods from April 1, 2022, to March 31, 2023, April 1, 2023, to March 31, 2024, and April 1, 2024, to March 31, 2025. Matthew K. Custer, also a PEO, similarly received equity awards with adjustments and inclusions for the same fiscal periods. Felicia Ladin and Jennifer C. Rogerson, non-PEO executives, also had their equity awards detailed for these three fiscal years. The filing focuses on the structure and reporting of these equity awards, indicating a consistent approach to executive incentives. No specific revenue or net income figures were provided in this particular DEF 14A excerpt, which primarily details compensation. The strategic outlook and key business changes are not explicitly covered beyond the compensation structure.
Why It Matters
This DEF 14A filing provides transparency into CYANOTECH CORP's executive compensation practices, specifically regarding equity awards for key personnel like Gerald R. Cysewski and Matthew K. Custer. For investors, understanding how executives are incentivized through equity can signal alignment with shareholder interests and long-term company performance. Employees might view these compensation structures as benchmarks for internal equity and career progression. In the competitive medicinal chemicals and botanical products sector, robust and transparent compensation packages are crucial for attracting and retaining top talent, potentially impacting CYANOTECH's ability to innovate and compete against rivals like AstaReal or Fuji Chemical Industry.
Risk Assessment
Risk Level: low — The risk level is low because this DEF 14A filing primarily details executive compensation, specifically equity awards for Gerald R. Cysewski, Matthew K. Custer, Felicia Ladin, and Jennifer C. Rogerson across three fiscal years. There are no indications of new financial liabilities, significant operational changes, or adverse events within this specific document. The filing is a routine disclosure of compensation structure.
Analyst Insight
Investors should note the consistent equity award structure for CYANOTECH's executives, indicating stable incentive alignment. However, without accompanying financial performance data, investors should seek the latest 10-K or 10-Q filings to assess the company's revenue and net income trends before making any investment decisions.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Gerald R. Cysewski | PEO | |
| Matthew K. Custer | PEO | |
| Felicia Ladin | Non-PEO Executive | |
| Jennifer C. Rogerson | Non-PEO Executive |
Key Numbers
- 2025-03-31 — Fiscal Year End (The most recent fiscal year for which executive compensation is detailed.)
- 2025-07-10 — Filing Date (Date the DEF 14A was filed with the SEC.)
- 0000768408 — Central Index Key (CIK) (Unique identifier for CYANOTECH CORP with the SEC.)
- 2833 — SIC Code (Standard Industrial Classification for Medicinal Chemicals & Botanical Products.)
- 96740 — ZIP Code (Business and mail address ZIP code for CYANOTECH CORP.)
Key Players & Entities
- CYANOTECH CORP (company) — filer of DEF 14A
- Gerald R. Cysewski (person) — Named Executive Officer (PEO) receiving equity awards
- Matthew K. Custer (person) — Named Executive Officer (PEO) receiving equity awards
- Felicia Ladin (person) — Non-PEO executive receiving equity awards
- Jennifer C. Rogerson (person) — Non-PEO executive receiving equity awards
- SEC (regulator) — regulator for DEF 14A filings
- 03 Life Sciences (company) — organization name associated with filer
- Nevada (regulator) — state of incorporation for CYANOTECH CORP
- Kailua Kona (company) — business address city for CYANOTECH CORP
- Hawaii (company) — business address state for CYANOTECH CORP
FAQ
What is the purpose of CYANOTECH CORP's DEF 14A filing?
CYANOTECH CORP's DEF 14A filing, dated July 10, 2025, primarily serves to disclose executive compensation, specifically detailing equity awards for named executive officers and other key personnel for the fiscal years ending March 31, 2025, 2024, and 2023.
Which executives are mentioned in CYANOTECH's DEF 14A regarding compensation?
The DEF 14A mentions Gerald R. Cysewski and Matthew K. Custer as Named Executive Officers (PEOs), and Felicia Ladin and Jennifer C. Rogerson as non-PEO executives, all of whom received equity awards detailed in the filing for the fiscal years ending March 31, 2025, and prior.
What type of compensation is detailed for CYANOTECH executives in this filing?
This DEF 14A filing specifically details equity awards, including adjustments and inclusions in the summary compensation table, for CYANOTECH's executives for the fiscal periods from April 1, 2022, through March 31, 2025.
When was CYANOTECH CORP's DEF 14A filed?
CYANOTECH CORP's DEF 14A was filed with the SEC on July 10, 2025, with a conformed period of report ending on August 21, 2025.
What is CYANOTECH CORP's primary industry classification?
CYANOTECH CORP is classified under the Standard Industrial Classification (SIC) code 2833, which corresponds to Medicinal Chemicals & Botanical Products, indicating its core business area.
Does this DEF 14A filing provide CYANOTECH's revenue or net income figures?
No, this specific DEF 14A filing excerpt primarily focuses on executive compensation details, particularly equity awards, and does not provide specific revenue or net income figures for CYANOTECH CORP.
What is the significance of equity awards for CYANOTECH's executives?
Equity awards are significant for CYANOTECH's executives as they align executive interests with shareholder value by tying a portion of their compensation to the company's stock performance, incentivizing long-term growth and profitability.
Where is CYANOTECH CORP's business located?
CYANOTECH CORP's business address is 73-4460 Queen Kaahumanu Hwy, Suite 102, Kailua Kona, Hawaii, 96740, indicating its operational base in Hawaii.
What is the fiscal year end for CYANOTECH CORP?
The fiscal year end for CYANOTECH CORP is March 31, as indicated by the compensation periods detailed in the DEF 14A filing, which consistently refer to periods ending on this date.
Are there any new risks identified in CYANOTECH's DEF 14A filing?
This DEF 14A filing primarily focuses on executive compensation and does not introduce or detail any new specific risks to CYANOTECH CORP's operations or financial health. It is a routine disclosure of compensation practices.
Industry Context
Cyanotech Corp operates within the medicinal chemicals and botanical products sector (SIC Code 2833). This industry is characterized by a focus on natural product extraction, purification, and development for health and wellness applications. Companies in this space often face competition from both established pharmaceutical players and emerging nutraceutical brands.
Regulatory Implications
As a publicly traded company, Cyanotech Corp is subject to SEC regulations, including the requirement to file DEF 14A statements. Compliance with disclosure rules regarding executive compensation and corporate governance is critical to maintaining investor confidence and avoiding potential penalties.
What Investors Should Do
- Review executive compensation details
- Monitor future filings for financial performance
Key Dates
- 2025-07-10: DEF 14A Filing — Indicates the company's disclosure of executive compensation and related governance matters for the fiscal year ending March 31, 2025.
- 2025-03-31: Fiscal Year End — The period covered by the executive compensation details provided in the filing.
Glossary
- DEF 14A
- A proxy statement filed by public companies with the SEC detailing information about the annual meeting of shareholders, including executive compensation, board of directors, and other corporate governance matters. (This filing specifically outlines the executive compensation structure and awards for Cyanotech Corp.)
- PEO
- Principal Executive Officer, typically the Chief Executive Officer or equivalent. (Identifies the highest-ranking executive officer whose compensation is detailed in the filing.)
- Equity Awards
- Awards granted to employees in the form of company stock or stock options, often used as a form of compensation and incentive. (A significant component of the executive compensation detailed for Cyanotech Corp's named officers.)
- Summary Compensation Table
- A table required by the SEC that summarizes the total compensation for a company's named executive officers for the last three fiscal years. (The filing indicates that equity awards are included in this table for Cyanotech Corp's executives.)
Year-Over-Year Comparison
This DEF 14A filing, dated July 10, 2025, details executive compensation for the fiscal year ending March 31, 2025, and prior years. While specific comparative financial metrics like revenue growth or margin changes are not present in this excerpt, the consistent reporting of equity awards for named executive officers across multiple fiscal periods suggests a stable approach to executive incentive structures. Investors should refer to previous filings to understand year-over-year changes in compensation components and any evolving risk disclosures.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on July 10, 2025 by Gerald R. Cysewski regarding CYANOTECH CORP (CYAND).